Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine
Cephalalgia · 2024
DOI: 10.1177/03331024241235139 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cephalalgia, 2024. Verfasst von Anand R Shewale und 4 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie, Chicago, IL, USA. Hauptthemen laut MEDLINE: Prescription Drug Overuse, Migraine Disorders, Headache Disorders, Secondary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Objective
Estimate health care resource utilization and costs associated with medication overuse headache and potential acute medication overuse.
Methods
A retrospective analysis was conducted with Clinformatics Data Mart data (1 January 2019–31 December 2019) that included continuously enrolled commercially insured adults with migraine (International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] code G43.xxx). Medication overuse headache was defined as ≥1 inpatient or ≥2 outpatient claims with an ICD-10-CM code G44.41/40 (drug-induced headache). Potential acute medication overuse was defined as possessing sufficient medication for >10 mean treatment days/month for ergots, triptans, opioids, or combination analgesics or >15 mean cumulative days/month for simple prescription analgesics (e.g., acetaminophen, aspirin, other non-opioid analgesics) for >6 consecutive months. All-cause and migraine-related health care resource utilization and costs were compared after adjusting for demographic and clinical characteristics.
Results
Among 90,017 individuals with migraine, the frequency of medication overuse headache/potential acute medication overuse was 12.6% (diagnosed medication overuse headache: 0.6%; potential acute medication overuse: 12.1%). Adjusted all-cause total costs ($31,235 vs $21,486; difference: $9,749 [ P < 0.001]) and adjusted migraine-related total costs ($9,770 vs $6,207; difference: $3,563 [ P < 0.001]) were higher in the medication overuse headache/potential acute medication overuse group versus those without medication overuse headache/potential acute medication overuse.
Conclusions
Individuals with diagnosed medication overuse headache/potential acute medication overuse had higher all-cause and migraine-related health care resource utilization and costs versus individuals without medication overuse headache/potential acute medication overuse, suggesting that improved migraine management is needed to reduce associated costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AbbVie, Chicago, IL, USA.
- HealthStatistics, Philadelphia, PA, USA.
- Albert Einstein College of Medicine, Bronx, NY, USA.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
ORCID-Profile: Richard B Lipton
Förderung
- AbbVie
Zitieren
APA
Shewale, A. R., Brandenburg, J. A., Burslem, K., Lipton, R. B., & Doshi, J. A. (2024). Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine. Cephalalgia. https://doi.org/10.1177/03331024241235139
Vancouver
Shewale AR, Brandenburg JA, Burslem K, Lipton RB, Doshi JA. Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine. Cephalalgia. 2024. doi:10.1177/03331024241235139
BibTeX
@article{Shewale2024,
author = {Shewale, Anand R and Brandenburg, Jennifer A and Burslem, Kate and Lipton, Richard B and Doshi, Jalpa A},
title = {Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024241235139}
}
EUVIMED